CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the resignations of Amir Nashat, managing partner at Polaris Partners, and Amy Schulman, venture partner at Polaris Partners and chief executive officer at Arsia Therapeutics and Lyndra Therapeutics, from BIND’s Board of Directors. The resignations of Dr. Nashat and Ms. Schulman are not a result of any dispute with the Company and were tendered in order to avoid a potential conflict of interest related to BIND’s current review of financial and strategic alternatives. In conjunction with these resignations, BIND’s Board of Directors has withdrawn Dr. Nashat as a nominee for election to the Board at the Company’s annual meeting of stockholders to be held on June 21, 2016 and has reduced the size of the Board from nine to seven members.

BIND Therapeutics initiated voluntary Chapter 11 bankruptcy protection on May 1, 2016 and is actively evaluating potential financial and strategic alternatives, which may include raising additional capital, licensing or divesting some of the Company’s proprietary technologies, or selling the company.

BIND plans to continue its development and collaboration activities in accordance with its current innovative medicines strategy throughout the Chapter 11 process.

About BIND Therapeutics

BIND Therapeutics is a biotechnology company developing novel targeted therapeutics, primarily for the treatment of cancer. BIND’S product candidates are based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. BIND is developing ACCURINS® with three different therapeutic objectives, both through internal research programs and with collaborators: Innovative medicines; enabling potent pathway inhibitors; and differentiated efficacy with approved drugs. BIND’s internal discovery efforts are focused on designing oligonucleotide and immune-oncology-based ACCURINS®.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada), Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals), Synergy Pharmaceuticals, PeptiDream and Affilogic to develop ACCURINS® based on their proprietary therapeutic payloads and/or targeting ligands. BIND's collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. BIND's collaboration with Pfizer has resulted in the selection of an Accurin candidate that is entering IND-enabling studies.

For more information, please visit the Company's web site at www.bindtherapeutics.com.